– Evaluation of product-related safety issues at the request of the CPMP and national competent authorities – Revision of pharmacovigilance-related guidelines in the light of experience and following Commission Directive 2000/38/EC amending Chapter Va of Council Directive 75/319/EEC – Development of Good Pharmacovigilance Practice – Contribution to multidisciplinary guidelines with regard to medicinal products used for xenogeneic cellular therapy and for treatment of pregnant women